These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37079262)

  • 1. Health-state utilities in long-term advanced melanoma survivors comparable with the general population.
    Egeler MD; van de Poll-Franse LV; Tissier R; Rogiers A; Boers-Sonderen MJ; van den Eertwegh AJ; Hospers GA; de Groot JWB; Aarts MJB; Kapiteijn E; Piersma D; Vreugdenhil G; van der Veldt AA; Suijkerbuijk KPM; Neyns B; Janssen KJ; Blank CU; Retèl VP; Boekhout AH
    Qual Life Res; 2023 Sep; 32(9):2517-2525. PubMed ID: 37079262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls.
    Boekhout AH; Rogiers A; Jozwiak K; Boers-Sonderen MJ; van den Eertwegh AJ; Hospers GA; de Groot JWB; Aarts MJB; Kapiteijn E; Ten Tije AJ; Piersma D; Vreugdenhil G; van der Veldt AA; Suijkerbuijk KPM; Rozeman EA; Neyns B; Janssen KJ; van de Poll-Franse LV; Blank CU
    Acta Oncol; 2021 Jan; 60(1):69-77. PubMed ID: 32924708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality-adjusted survival of nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone among treatment-naive patients with advanced melanoma: a quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis.
    McDermott DF; Shah R; Gupte-Singh K; Sabater J; Luo L; Botteman M; Rao S; Regan MM; Atkins M
    Qual Life Res; 2019 Jan; 28(1):109-119. PubMed ID: 30191365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death.
    Hatswell AJ; Pennington B; Pericleous L; Rowen D; Lebmeier M; Lee D
    Health Qual Life Outcomes; 2014 Sep; 12():140. PubMed ID: 25214238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors.
    Mamoor M; Postow MA; Lavery JA; Baxi SS; Khan N; Mao JJ; Rogak LJ; Sidlow R; Thom B; Wolchok JA; Korenstein D
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab.
    Rogiers A; Leys C; Lauwyck J; Schembri A; Awada G; Schwarze JK; De Cremer J; Theuns P; Maruff P; De Ridder M; Bernheim JL; Neyns B
    J Immunol Res; 2020; 2020():2192480. PubMed ID: 32775464
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma.
    Almutairi AR; Alkhatib NS; Oh M; Curiel-Lewandrowski C; Babiker HM; Cranmer LD; McBride A; Abraham I
    JAMA Dermatol; 2019 Jan; 155(1):22-28. PubMed ID: 30477000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with melanoma expressed as utilities and disability weights.
    Tromme I; Devleesschauwer B; Beutels P; Richez P; Leroy A; Baurain JF; Cornelis F; Bertrand C; Legrand N; Degueldre J; Thomas L; Legrand C; Lambert J; Haagsma J; Speybroeck N
    Br J Dermatol; 2014 Dec; 171(6):1443-50. PubMed ID: 25039853
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The burden of colorectal cancer survivors in the Netherlands: costs, utilities, and associated patient characteristics.
    Mulder FECM; van Roekel EH; Bours MJL; Weijenberg MP; Evers SMAA
    J Cancer Surviv; 2022 Oct; 16(5):1055-1064. PubMed ID: 34510364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating EQ-5D and OAB-5D health state utilities for patients with overactive bladder.
    Desroziers K; Aballéa S; Maman K; Nazir J; Odeyemi I; Hakimi Z
    Health Qual Life Outcomes; 2013 Nov; 11():200. PubMed ID: 24246044
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Catalog and comparison of societal preferences (utilities) for lung cancer health states: results from the Cancer Care Outcomes Research and Surveillance (CanCORS) study.
    Tramontano AC; Schrag DL; Malin JK; Miller MC; Weeks JC; Swan JS; McMahon PM
    Med Decis Making; 2015 Apr; 35(3):371-87. PubMed ID: 25670839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England.
    Meng Y; Hertel N; Ellis J; Morais E; Johnson H; Philips Z; Roskell N; Walker A; Lee D
    Eur J Health Econ; 2018 Nov; 19(8):1163-1172. PubMed ID: 29524005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors.
    O'Reilly A; Hughes P; Mann J; Lai Z; Teh JJ; Mclean E; Edmonds K; Lingard K; Chauhan D; Lynch J; Au L; Ludlow A; Pattison N; Wiseman T; Turajlic S; Gore M; Larkin J; Husson O
    Support Care Cancer; 2020 Feb; 28(2):561-570. PubMed ID: 31089820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.
    Oh A; Tran DM; McDowell LC; Keyvani D; Barcelon JA; Merino O; Wilson L
    J Manag Care Spec Pharm; 2017 Jun; 23(6):653-664. PubMed ID: 28530525
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Self-reported depression in cancer survivors versus the general population: a population-based propensity score-matching analysis.
    Lee SJ; Cartmell KB
    Qual Life Res; 2020 Feb; 29(2):483-494. PubMed ID: 31707694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
    Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
    Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilities Estimated from PROMIS Scales for Cost-Effectiveness Analyses in Stroke.
    Thompson NR; Lapin BR; Katzan IL
    Med Decis Making; 2023 Aug; 43(6):704-718. PubMed ID: 37401739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Which approach is better in eliciting health state utilities from breast cancer patients? Evidence from mainland China.
    Li S; Wang M; Liu L; Chen G
    Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12965. PubMed ID: 30499193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Uneven recovery patterns of compromised health-related quality of life (EQ-5D-3 L) domains for breast Cancer survivors: a comparative study.
    Yu J; Son WS; Lee SB; Chung IY; Son BH; Ahn SH; Jo MW; Lee JW
    Health Qual Life Outcomes; 2018 Jul; 16(1):143. PubMed ID: 30029669
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study.
    Long GV; Atkinson V; Ascierto PA; Robert C; Hassel JC; Rutkowski P; Savage KJ; Taylor F; Coon C; Gilloteau I; Dastani HB; Waxman IM; Abernethy AP
    Ann Oncol; 2016 Oct; 27(10):1940-6. PubMed ID: 27405322
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.